Melanoma

In an interview with Targeted Oncology, Ryan J. Sullivan, MD, discussed the history of tumor infiltrating lymphocyte therapy, how new data may lead to approved agents in the future, and other ways tumor infiltrating lymphocytes may be used in advanced melanoma.

In patients with completely resected stage IIB or IIC melanoma, use of adjuvant nivolumab achieved a 58% reduction in the risk of recurrence or death.

Data from the DREAMseq trial have answered a lingering question of how to sequence therapy for patients with advanced BRAF-mutant melanoma. This research supports immunotherapy in the first-line setting, followed by BRAK/MEK inhibitors.

Genevieve Boland, MD, PhD, discusses the latest updates to the melanoma treatment landscape.

With an overall response rate of 50% and greater than 5 months median progression-free survival in patients with first-line metastatic uveal melanoma, darovasertib and crizotinib shows a compelling clinical efficacy profile.

Results from the phase 2 SWOG S181 study show that for patients given pembrolizumab in the neoadjuvant setting had a significant EFS benefit compared with adjuvant pembrolizumab.

Naporafenib, in combination with several therapies, showed strong efficacy for patients with unresectable or metastatic melanoma.

The oncolytic virus T-VEC showed consistent improvements at 5 years for patients with stage IIIB to IVM1a melanoma.

A novel tumor-infiltrating lymphocyte therapy showed a 50% reduction in the risk of death for patients with stage IIIC/IV unresectable, treatment-refractory melanoma.

A patient enrolled in the phase 1 NADOM trial of darovasertib alone in non-metastatic uveal melanoma shows early signs of clinical efficacy.

Enrollment has begun for a phase 2 study of a polarized dendritic cell vaccine plus interferon alpha-2b, rintatolimod, and celecoxib in melanoma with PD1/PD-L1-resistance.

A biologics license application for lifileucel has been initiated by the FDA following positive findings of the phase 2 C-144-01 trial in advanced melanoma.

In an interview with Targeted Oncology, Gerald Falchook, MD, discusses the efficacy and safety of cobolimab with or without nivolumab and dostarlimab, as evaluated in the phase 1 AMBER trial.

The recruitment of patients with melanoma has been completed in the phase 2 INITIUM clinical trial. Topline results from the study are expected to be reported in early 2023.

Adjuvant pembrolizumab improved distant metastasis-free survival and longer follow up for recurrence-free survival in patients with resected stage IIB or stage IIC melanoma, according to data discussed at the 2022 ASCO Annual Meeting.

Ongoing and proposed melanoma research will naturally continue to evaluate new treatment types.

The phase 1/2 THETIS clinical trial is actively recruiting patients with metastatic melanoma to be treated with the investigation combination of ATL001 and an immune checkpoint inhibitor.

The phase 3 COMBI-i trial demonstrated that spartalizumab plus dabrafenib and trametinib has modest efficacy in BRAF V600-positive metastatic melanoma, but no progression-free survival benefit when compared with dabrafenib and trametinib alone.

Katherine E. Poruk, MD, reviews the use of complete axillary lymph node dissection and the Multicenter Selective Lymphadenectomy Trial II for Melanoma Monday.

With an FDA orphan drug designation for the treatment of patients with uveal melanoma, darovasertib is being actively investigated in a phase 1/2 clinical trial.

Results from the melanoma cohort the MATINS trial will be shared at the 18th Congress of the European Association of Dermato-Oncology.

For advanced melanoma that is resistant to anti–PD-1 therapies, the addition of BO-112 to pembrolizumab appears to be effective and safe.

Barriers to improving BRAF testing turnaround time in patients with melanoma have been identified in a retrospective analysis of real-world data collected in Canada.

Response were observed with the combination of sotigalimab and pembrolizumab in patients with metastatic melanoma treated in a phase 1/2 study.

According to a phase 1/2 study, nivolumab plus PD-L1/IDO peptide vaccine may be effective for the treatment of patients with metastatic melanoma.

The PROPHETIC trial of a predictive diagnostic analysis platform expanded to a new site at Roswell Park Comprehensive Cancer Center in Buffalo, New York.

The FDA has granted approval to the fixed-dose combination of relatlimab plus nivolumab for the treatment of adult and pediatric patients with unresectable or metastatic melanoma.

Relatlimab plus nivolumab demonstrated reduction in risk of progression or death and numerically improved overall survival compared to nivolumab alone.

All primary end points in the phase 3 study of bempegaldesleukin plus nivolumab for the treatment of metastatic melanoma were missed, but analyses are ongoing.

In PIVOT IO-001, patients with metastatic melanoma are no longer being enrolled and treatment arms have been unblinded after the combination of bempegaldesleukin and nivolumab did not meet its coprimary end points.